Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2

    November 2025 in “ SKIN The Journal of Cutaneous Medicine ”
    Ruth Ann Vleugels, Bianca Maria Piraccini, Natasha Atanaskova Mesinkovska … Brett King
    Studysummary This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on skin.dermsquared.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment American Journal of Clinical Dermatology · 2025
    2. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    3. Alopecia Areata: Current Understanding and Management Journal der Deutschen Dermatologischen Gesellschaft · 2022